PuMP: Oncolytic HSV1 MVR-C5252 in Patients with rHGG (Recurrent Glioma)

Purpose of this Study

We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.

Who Can Participate?

Eligibility

Adults ages 18+ who are diagnosed with recurrent high-grade glioma.

For more information about this study, please call 919-668-3726.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

If you join the study, you will:<ul>
<li>Have a physical and neurological exam and other tests</li>
<li>Have magnetic resonance imaging (MRI) of the brain</li>
<li>Have blood draws</li>
<li>Have brain tumor biopsy and testing of tumor sample</li>
<li>Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head</li>
<li>Get the study drug infused through an external pump and the implanted catheter</li></ul>

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

The PuMP Trial: A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma

Principal Investigator

Mustafa
Khasraw

Protocol Number

PRO00112883

NCT ID

NCT06126744

Phase

I

Enrollment Status

Open to Enrollment